
Tcr2 Therapeutics Inc is a biotechnology business based in the US. Tcr2 Therapeutics shares (TCRR) are listed on the NASDAQ and all prices are listed in US Dollars. Tcr2 Therapeutics employs 145 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Tcr2 Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TCRR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Tcr2 Therapeutics stock price (NASDAQ: TCRR)
Use our graph to track the performance of TCRR stocks over time.Tcr2 Therapeutics shares at a glance
Latest market close | $2.94 |
---|---|
52-week range | $2.07 - $19.03 |
50-day moving average | $2.41 |
200-day moving average | $4.65 |
Wall St. target price | $13.89 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.81 |
Buy Tcr2 Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Tcr2 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Tcr2 Therapeutics price performance over time
Historical closes compared with the close of $2.94 from 2022-06-29
1 week (2022-06-23) | 4.63% |
---|---|
1 month (2022-05-26) | N/A |
3 months (2022-03-30) | 10.53% |
6 months (2021-12-30) | -38.62% |
1 year (2021-06-30) | -82.08% |
---|---|
2 years (2020-06-30) | -80.86% |
3 years (2019-06-28) | 14.31 |
5 years (2017-06-26) | N/A |
Tcr2 Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -17.96% |
Return on equity TTM | -35.51% |
Profit margin | 0% |
Book value | $6.62 |
Market capitalisation | $110.2 million |
TTM: trailing 12 months
Tcr2 Therapeutics share dividends
We're not expecting Tcr2 Therapeutics to pay a dividend over the next 12 months.
Tcr2 Therapeutics share price volatility
Over the last 12 months, Tcr2 Therapeutics's shares have ranged in value from as little as $2.065 up to $19.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tcr2 Therapeutics's is 2.197. This would suggest that Tcr2 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tcr2 Therapeutics overview
TCR2 Therapeutics Inc. , a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016.
Tcr2 Therapeutics in the news
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Frequently asked questions
What percentage of Tcr2 Therapeutics is owned by insiders or institutions?Currently 0.891% of Tcr2 Therapeutics shares are held by insiders and 75.455% by institutions. How many people work for Tcr2 Therapeutics?
Latest data suggests 145 work at Tcr2 Therapeutics. When does the fiscal year end for Tcr2 Therapeutics?
Tcr2 Therapeutics's fiscal year ends in December. Where is Tcr2 Therapeutics based?
Tcr2 Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142 What is Tcr2 Therapeutics's ISIN number?
Tcr2 Therapeutics's international securities identification number is: US87808K1060 What is Tcr2 Therapeutics's CUSIP number?
Tcr2 Therapeutics's Committee on Uniform Securities Identification Procedures number is: 87808K106
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert